INTRODUCTION
============

Subclinical hypothyroidism (SCH), which is defined as an isolated elevation of thyroid-stimulating hormone (TSH) levels with a normal free thyroxine (fT4) level, is a relatively common disorder. Most experts agree that SCH represents early, mild thyroid failure \[[@B1]\] and this issue is becoming increasingly recognized because the performance of thyroid function tests have substantially increased in primary care settings \[[@B2]\]. Despite the intuitive appeal of the relationship between elevated TSH levels or SCH and adverse cardiovascular (CV) outcomes, it remains unclear whether variations in thyroid hormone levels within the normal range are also associated with mortality endpoints \[[@B3]\]. The precise definition and clinical significance of SCH are also confounded by controversies regarding the correct upper limit of the reference range for serum TSH. In fact, the optimal TSH cutoff values and clinical significance of these subclinical abnormalities are even more controversial \[[@B4]\]. Typically, the treatment of SCH is considered only for patients who are pregnant, infertile, exhibit associated symptoms, or have a high risk of progression to overt hypothyroidism \[[@B3]\]. Although there is a high prevalence of SCH, the evidence supporting screening for this disorder and the benefits and risks of its treatment remain controversial. Therefore, the primary goals of the present narrative review were to assess current evidence regarding the clinical aspects of SCH and cardiovascular disease (CVD) and to evaluate the mechanisms that are likely to underlie this relationship. To accomplish these goals, an updated search of PubMed was conducted for the most recent articles investigating the risks and treatment of SCH that were published prior to 2015.

EPIDEMIOLOGY
============

SCH has various causes of which the most common (60% to 80%) is chronic autoimmune thyroiditis associated with the presence of anti-thyroid peroxidase antibodies, which is a marker of chronic lymphocytic (Hashimoto\'s) thyroiditis \[[@B4]\]. Hashimoto\'s thyroiditis is more common in girls and women, but the overall incidence increases with age in both sexes \[[@B1]\]. Patients who have been treated for overt thyroid failure often exhibit SCH due to inadequate thyroid hormone supplementation, poor adherence to the treatment regimen, drug interactions, or the inadequate monitoring of treatment \[[@B1]\]. The prevalence of SCH varies according to population, age, sex, race, region, and method of TSH measurement \[[@B1]\]. Thus, it is necessary that the normal reference range for TSH levels be standardized and that appropriate quality control procedures be established by each laboratory investigating this phenomenon \[[@B3]\]. In general, SCH is defined as a TSH level greater than 4.0 to 6.0 mIU/L \[[@B5]\]. The prevalence of SCH is relatively high and ranges from 4% to 20% in the adult population with women, elderly people, and iodine-sufficient populations being affected more often \[[@B6]\]. For example, in a recent study using Korean population-based cohorts, the prevalence of SCH was reported to be 11.3% \[[@B7]\].

CARDIOVASCULAR RISK FACTORS
===========================

The adverse clinical effects associated with overt thyroid disorders are well known and, given the multiple actions of thyroid hormones on the heart, vessels, bones, and brain, long-term adverse outcomes may manifest as subclinical levels of dysfunction. [Table 1](#T1){ref-type="table"} provides an overview of the findings from studies investigating the associations of SCH with various clinical conditions.

For example, the relationship between pathological thyroid dysfunction and body weight is well established \[[@B8][@B9]\]. Cross-sectional studies using population cohorts have demonstrated that variations in thyroid function within the population reference range have a substantial impact on weight and body mass index (BMI). Higher levels of TSH are associated with an increased BMI \[[@B8]\] and rising TSH levels which, in turn, are associated with enhanced weight gain \[[@B9]\].

Additionally, an increasing amount of evidence indicates that higher levels of TSH are associated with worsening blood pressure (BP) and altered lipid levels. A cross-sectional study demonstrated that subjects with SCH exhibit increased BP \[[@B10]\] and a population-based study observed positive linear associations between TSH levels and systolic and diastolic BP \[[@B11]\]. Similarly, a recent meta-analysis found that SCH is associated with higher systolic BP \[[@B12]\]. Thyroid hormones exert multiple effects on the regulation, absorption, and metabolism of lipid synthesis as well. Previous studies have consistently demonstrated that elevated levels of serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), apolipoprotein B, lipoprotein(a), and possibly triglycerides (TG) are reversed in individuals with overt hypothyroidism following levothyroxine (T4) therapy \[[@B13]\]. A number of studies have reported significant increases in serum TC, LDL-C, and TG in patients with SCH \[[@B13]\] and the findings of a meta-analysis found that the TC, LDL-C, and TG levels of SCH subjects are significantly increased relative to euthyroid individuals \[[@B14]\].

Similarly, a Korean study demonstrated that SCH subjects with an intermediate-to-high risk of CVD had higher coronary calcium scores than euthyroid subjects \[[@B15]\] and Marfella et al. \[[@B16]\] identified enhanced inflammatory activity in the asymptomatic carotid plaques of SCH subjects compared to euthyroid subjects. SCH can also lead to vascular problems characterized by increased vascular stiffness and endothelial dysfunction \[[@B17]\]. Studies of euthyroid individuals have shown that fT4 and triiodothyronine (T3) levels, even within the normal range, are inversely associated with the presence and severity of coronary and carotid atherosclerosis as well as carotid artery intima media thickness \[[@B18]\]. Other possible explanations for the increased CV risk in persons with SCH include hypercoagulability, insulin resistance, oxidative stress \[[@B4]\], and endothelial dysfunction \[[@B17]\].

METABOLIC SYNDROME
==================

Metabolic syndrome (MetS) is a condition characterized by a cluster of metabolic disorders including abdominal obesity, insulin resistance/glucose intolerance, dyslipidemia, and hypertension \[[@B19]\]. It has been well documented that MetS is associated with increased risks of all-cause mortality and CVD \[[@B19]\]. A systemic review by Iwen et al. \[[@B20]\] found convincing evidence supporting the major impact of SCH on all components of MetS and a cross-sectional analysis of cohort studies highlighted the fact that the odds of having MetS are positively associated with TSH levels within the reference range \[[@B9]\]. Additionally, cross-sectional and longitudinal follow-up studies from Japan observed strong associations between SCH and MetS \[[@B21]\]. In Korea, high normal TSH levels were significantly associated with the increased prevalence of MetS in 7,270 euthyroid men and women \[[@B22]\] and another study of 2,760 young Korean female volunteers with normal TSH levels found that the high TSH group had a 2-fold greater risk of MetS than subjects in the low TSH group \[[@B23]\].

HEART FAILURE
=============

It is well known that thyroid hormones act on the heart and vasculature and, as a result, the impact of subclinical thyroid dysfunction on the CV system has recently become an important topic of research. SCH can lead to impaired systolic and diastolic cardiac function \[[@B24]\] and symptomatic SCH patients often complain of reduced exercise tolerance during effort \[[@B25]\]. This same study found that a slowed rate of left ventricular relaxation might critically impair ventricular filling during exercise and result in left ventricular systolic dysfunction. Older people with SCH and a high CV risk appear to be at an increased risk of incident heart failure \[[@B26]\] and SCH was found to affect left ventricular dysfunction, although this abnormality may be reversed by T4 substitutive therapy \[[@B27]\]. Likewise, a recent cardiac magnetic resonance spectroscopic study demonstrated that early cardiac bio-energetic impairments in SCH patients are reversible with T4 therapy \[[@B28]\]. A pooled analysis from six prospective cohorts also found that the risk of heart failure events increases in conjunction with higher TSH levels \[[@B29]\].

CARDIOVASCULAR DISEASE
======================

Many studies have examined the relationship between SCH and CVD. Studies of euthyroid individuals observed a positive association between TSH levels and mortality due to coronary heart disease (CHD) \[[@B11][@B30]\]. TSH levels within the normal range are inversely associated with all-cause mortality \[[@B31][@B32][@B33]\] and adult Taiwanese subjects with SCH were shown to have an increased risk for all-cause mortality and CVD death over a 10-year period \[[@B34]\]. However, other studies did not find any associations with all-cause \[[@B35][@B36][@B37][@B38]\] or CV \[[@B31][@B36][@B39]\] mortality rates. These discrepant findings may be due to differences in sample size and power, the inconsistent age and sex ratios of the study populations, or the varied iodine intakes of different regions. Two meta-analyses \[[@B40][@B41]\] investigating this matter demonstrated that SCH may be associated with a modest increase in the risks of CHD and mortality, particularly in subjects with higher TSH levels. A more recent review of the clinical consequences of variations in thyroid function within the normal reference range found that even modest elevations of TSH may have substantial health outcomes, including CV mortality \[[@B9]\]. In a Korean cohort that was followed for 10 years, elevated serum TSH levels significantly increased the risk of CVD by approximately 20% per one standard deviation in males \[[@B7]\]. More recently, fT4 and fT3 levels within the normal range were inversely associated with the risks of all-cause and cancer mortality in a Korean cohort of euthyroid men and women (*n*=212,456) \[[@B42]\].

EFFECTS OF REPLACEMENT THERAPY
==============================

A number of placebo-controlled studies have assessed the effects of T4 replacement therapy on the symptoms of patients with SCH. However, the reported benefits of various SCH treatments are limited and evidence regarding the association of SCH with CVD remains controversial \[[@B43]\]. An intervention study of 56 women with SCH identified elevated systolic and diastolic BP and increased serum cholesterol and homocysteine levels compared to healthy controls \[[@B44]\]; these factors were normalized after 18 months of T4 therapy. A systematic review of 13 heterogeneous studies concluded that T4 treatment leads to a reduction in serum TC and LDL-C levels in patients with SCH \[[@B45]\]; this finding has been confirmed in subsequent randomized controlled trials (RCTs) \[[@B17]\]. However, to date, clinical trials have not consistently shown the beneficial effects of T4 treatment on serum lipid levels in SCH patients \[[@B13]\]. Nonetheless, reductions in carotid intima-media thickness \[[@B46]\] and improvements in brachial artery endothelial function have been observed in individuals with SCH following T4 replacement \[[@B17]\]. Thus, the negative effects of SCH on CV function might be improved or reversed by replacement doses of T4. Although only a few studies investigating the CV effects of T4 have been double-blinded and placebo-controlled, these trials concur that T4 replacement therapy improves systolic and diastolic heart function, endothelial function, and carotid intima-media thickness \[[@B46]\]. Similarly, in a small RCT, the normalization of TSH levels following T4 replacement therapy led to an improvement in cardiac function \[[@B24]\]. Moreover, there are new data supporting improved outcomes in younger (\<70 years) CHD patients treated with T4 \[[@B47]\]. On the other hand, a Cochrane review from 2007 assessed 12 RCTs of T4 replacement in patients with SCH and concluded that replacement therapy for SCH did not result in improved survival or decreased CV morbidity \[[@B48]\].

The indications for the screening of SCH and the determination of TSH threshold levels for the treatment of SCH have remained a clinical controversy for over many years. Additional observational data are unlikely to adequately address the uncertainties associated with the risks of SCH or the potential benefits and risks of replacement therapy. These concerns will be best addressed in an appropriately powered RCT that assesses clinical outcomes. The European Commission has now funded such a trial; the Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism (TRUST) study. The TRUST study is a multicenter, double-blinded, placebo-controlled randomized trial designed to assess the multimodal effects of thyroid hormone replacement in 3,000 adults 65 years of age and older with persistent SCH (Clinicaltrials.gov: NCT01660126). In addition to CV events such as CHD, stroke, and heart failure, this trial will evaluate disease-specific and health-related quality of life, muscle function, and cognitive function. This study should definitively clarify the populations that may benefit from T4 replacement by assessing multiple clinical outcomes as well as whether these benefits may be offset by the potential adverse effects of replacement therapy, such as atrial fibrillation and osteoporosis.

DISCUSSION
==========

The significance of SCH is now widely studied and the data continue to accumulate. In summary, the present review has highlighted the fact that SCH is associated with an increased risk of developing a wide range of adverse health outcomes and that SCH might represent a potentially modifiable risk factor of CVD and mortality. Therefore, understanding the prevalence and risk factors of SCH could aid in the prevention of CVD in this population. However, until the results of the TRUST study are published and current clinical recommendations \[[@B3][@B49]\] are updated, the decision to treat or not treat an SCH patient will be based on clinical judgment, clinical practice guidelines, and expert opinion.
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  Outcome                    Associations   Parameter                     Evidence quality
  -------------------------- -------------- ----------------------------- ------------------
  Blood pressure             Yes            Thyroid-stimulating hormone   Good
  Lipid levels               Yes            Thyroid-stimulating hormone   Good
  Metabolic syndrome         Yes            Thyroid-stimulating hormone   Moderate
  Heart failure              Possible       Thyroid-stimulating hormone   Moderate
  Cardiovascular mortality   Possible       Thyroid-stimulating hormone   Moderate
